Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
  • C07F9/6503—Five-membered rings
  • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
  • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
  • C07F9/6518—Five-membered rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
  • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Definitions

• This invention relates to novel water-soluble azole compounds useful for the treatment of serious systemic fungal infections and suitable for both oral and, particularly, parenteral administration. More particularly, the invention relates to novel water-soluble prodrugs having the general formula:
• A is the non-hydroxy portion of a triazole antifungal compound of the type containing a secondary or tertiary hydroxy group
• R and R 1 are each independently hydrogen or (C ⁇ -C 6 )alkyl, or pharmaceutically acceptable salts thereof.
• Triazole antifungal compounds are well known in the prior art. Of the several classes known, one particularly potent class contains a tertiary hydroxyl group.
• U. S. Patent 5,648,372 discloses that (2R,3R)-3-[4-(4- cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)- 1 -( 1 H- 1 ,2,4-triazol- 1 -yl)- butan-2-ol has anti-fungal activity.
• WO 97/28169 discloses that a phosphate moiety can be attached directly to the tertiary hydroxyl portion of the anti-fungal compound, e.g. the compound having the formula
• X is OP(O)(OH) 2 or an easily hydrolyzable ester OC(O)RNR l'rR>2.
• WO 95/17407 discloses water-soluble azole prodrugs of the general formula
• X is P(O)(OH) 2 , C(O)-(CHR') n -OP(O)(OH) 2 or C(O)-(CHR') ⁇
• WO 96/38443 discloses water-soluble azole prodrugs of the general formula
• U.S. Patent 5,883,097 discloses water-soluble amino acid azole prodrugs such as the glycine ester
• European Patent Application 604910 discloses phosphonooxymethyl taxane derivatives of the general formula
• R 1 ' , R 2" , R 3' , R 6' or R 7' is OCH 2 OP(O)(OH) 2 .
• European Patent Application 639577 discloses phosphonooxymethyl taxane derivatives of the formula T-[OCH 2 (OCH 2 ) m OP(O)(OH) 2 ] n wherein T is a taxane moiety bearing on the C13 carbon atom a substituted 3-amino-2- hydroxypropanoyloxy group; n is 1, 2 or 3; m is 0 or an integer from 1 to 6 inclusive, and pharmaceutically acceptable salts thereof.
• WO 99/38873 discloses O-phosphonooxymethyl ether prodrugs of a diaryl 1,3,4-oxadiazolone potassium channel opener.
• triazole anti-fungal compounds containing a secondary or tertiary hydroxyl group including (2R,3R)-3-[4-(4- cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)- 1 -( 1 H- 1 ,2,4-triazol- 1 -yl)-butan- 2-ol, may be converted into prodrugs with superior properties to those previously disclosed by attaching a phosphate containing moiety via a linking group.
• the invention covers compounds of the formula:
• A is the non-hydroxy portion of a triazole antifungal compound of the type containing a secondary or tertiary hydroxy group, R and R! are each independently hydrogen or (C1-C6) alkyl, or pharmaceutically acceptable salts thereof.
• the compounds of general formula I function as "prodrugs" when administered in vivo, being converted to the biologically active parent azole in the presence of alkaline phosphatase.
• Preferred among the compounds of formula I are those wherein R and R are both hydrogen.
• A represents the non-hydroxy portion of a triazole antifungal compound of the type containing a tertiary hydroxy group.
• R ⁇ represents phenyl substituted by one or more (preferably 1-3) halogen atoms
• R4 represents H or CH3
• Nitrogen containing heterocycles which R ⁇ may represent include triazolyl, pyrimidinyl, and thiazolyl.
• Specific examples of A include, but are not limited to, the following:
• -C 6 )alkyl refers to a straight or branched chain saturated aliphatic group having 1 to 6 carbon atoms such as methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, t-butyl, n-pentyl, n-hexyl, etc.
• pharmaceutically acceptable salt as used herein is intended to include phosphate salts with such counterions as ammonium, metal salts, salts with amino acids, salts with amines and salts with other bases such as piperidine or morpholine. Both mono- and bis-salts are intended to be encompassed by the term “pharmaceutically acceptable salts”.
• Specific embodiments include ammonium, sodium, calcium, magnesium, cesium, lithium, potassium, barium, zinc, aluminum, lysine, arginine, histidine, methylamine, ethylamine, t- butylamine, cyclohexylamine, N-methylglucamine, ethylenediamine, glycine, procaine, benzathene, diethanolamine, triethanolamine, piperidine and morpholine.
• halogen as used herein includes chloro, bromo, fluoro and iodo, and is preferably chloro or fluoro, and most preferably fluoro.
• the compounds of the present invention can be solvated or non-solvated.
• a preferred solvate is a hydrate.
• a most preferred embodiment of the present invention is (2R,3R)-3-[4-(4- cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)- 1 -( 1 H- 1 ,2,4-triazol- 1 -yl)-2- [(dihydrogen phosphonoxy)methoxy]butane or a pharmaceutically acceptable salt thereof.
• This prodrug exhibits much improved aqueous solubility (>10 mg/mL at pH 7, 5-6 mg/mL at pH 4.3) compared with the parent compound which enables it to be used for parenteral administration as well as oral administration.
• This compound is also stable in solution, can be isolated in crystalline form and is readily converted to parent drug in vivo.
• A represents the non-hydroxy portion of a triazole antifungal compound of the type containing a tertiary or secondary hydroxyl group
• Pr represents a conventional hydroxy-protecting groups such as t- butyl, benzyl or allyl
• R and R 1 are each independently hydrogen or (C]-C 6 )alkyl. Most preferably, R and R 1 are both hydrogen.
• the antifungal parent compound of interest, II is converted into the phosphate intermediate IV by O-alkylation with chloride intermediate III in the presence of a suitable base such as sodium hydride, potassium hydride, sodium amide, sodium t-butoxide, potassium t-butoxide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, or combinations thereof such as sodium hydride plus sodium bis(trimethylsilyl)amide.
• a suitable base such as sodium hydride, potassium hydride, sodium amide, sodium t-butoxide, potassium t-butoxide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, or combinations thereof such as sodium hydride plus sodium bis(trimethylsilyl)amide.
• This reaction step may be carried out in an inert organic solvent such as tetrahydrofuran, methyl-tetrahydrofuran, methyl t-butyl ether, diethylether or dimethylacetamide at a temperature of from about 0 ° to 50 °C, more preferably between about 20 ° to 40 °C, and most preferably at about 40° C.
• the most preferred base is sodium hydride and the most preferred solvent is tetrahydrofuran.
• the most preferred R and R 1 groups are hydrogen.
• Ester intermediate IV is then subjected to a conventional deprotection step to remove the hydroxyl-protecting groups Pr.
• the reagents used in such step will depend on the particular hydroxyl-protecting group used, but will be well known to those skilled in the art.
• the most preferred hydroxy protecting group is the t- butyl group which can be removed with trifluoroacetic acid, hydrochloric acid or formic acid in an appropriate inert organic solvent.
• the inert solvent may be, for example, methylene chloride, dichloroethane, methylbenzene or trifluoromethyl benzene.
• the deprotection step in trifluoroacetic acid in methylene chloride at a temperature of from about 0 ° to 40 °C, most preferably at a temperature of about 0-5 °C.
• the final product I may then be recovered and purified by conventional procedures such as reverse phase C-18 column chromatography or solvent extraction.
• End product I may, of course, be converted by conventional means to a desired pharmaceutically acceptable salt as described above.
• the greatly increased yield of phosphate ester IV allows the final product I to be also obtained in greatly increased yield.
• the source of iodide ion is preferably sodium iodide, but may also include lithium iodide, cesium iodide, cadmium iodide, cobalt iodide, copper iodide, rubidium iodide, barium iodide, zinc iodide and calcium iodide.
• About 2-3 equivalents of the iodide salt is generally used per equivalent of parent compound A-OH.
• elemental iodine is used in the coupling step, about 0.1 to 1.0 equivalent of iodine, preferably 0.5 equivalent, is employed per equivalent of parent compound A-OH.
• the bases and solvents which are used when iodine or iodide ion is used are the same as those described above when reagent III is used per se.
• compositions comprising, in addition to the active triazole ingredient, a pharmaceutically acceptable carrier, adjuvant or diluent.
• the compounds may be administered by a variety of means, for example, orally, topically or parenterally (intravenous or intramuscular injection).
• the pharmaceutical compositions may be in solid form such as capsules, tablets, powders, etc. or in liquid form such as solutions, suspensions or emulsions.
• Compositions for injection may be prepared in unit dose form in ampules or in multidose containers and may contain additives such as suspending, stabilizing and dispersing agents.
• the compositions may be in ready-to-use form or in powder form for reconstitution at the time of delivery with a suitable vehicle such as sterile water.
• the compounds of the present invention can be administered in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, or cream. Additionally, they may be incorporated (at a concentration up to 10%) into an ointment consisting of a white wax or soft, white paraffin base together with the required stabilizers and/or preservatives.
• the compounds of the invention are useful because they possess pharmacological activities in animals, including particularly mammals and most particularly, humans.
• the compounds of the present invention are useful for the treatment or prevention of topical fungal infections, including those caused by species of Candida, Trichophyton, Microsporum, or Epidermophyton.
• they are useful for the treatment of mucosal infections caused by Candida albicans. They can also be used in the treatment of systemic fungal infections caused, for example, by species of Candida albicans, Cryptococcus neoformans, Aspergillus flavus, Aspergillus fumigatus, Coccidioides, Paracoccidiodes, Histoplasma, or Blastomyces.
• a method of treating a fungal infection which comprises administering a therapeutically effective amount of the compound to a host, particularly a mammalian host and most particularly a human patient.
• a host particularly a mammalian host and most particularly a human patient.
• the use of the compounds of the present invention as pharmaceuticals and the use of the compounds of the invention in the manufacture of a medicament for the treatment of fungal infections are also provided.
• the dosage to be administered depends, to a large extent, on the particular compound being used, the particular composition formulated, the route of administration, the nature and condition of the host and the particular situs and organism being treated. Selection of the particular preferred dosage and route of application, then, is left to the discretion of the physician or veterinarian. In general, however, the compounds may be administered parenterally or orally to mammalian hosts in an amount of from about 5 mg/day to about 1.0 g/day. These doses are exemplary of the average case, and there can be individual instances where higher or lower dosages are merited, and such dosages are within the scope of this invention. Furthermore, administration of the compounds of the present inventions can be conducted in either single or divided doses.
• the in vitro evaluation of the antifungal activities of the compounds of the invention can be performed by determining the minimum inhibitory concentration
• MIC MIC
• the MIC is the concentration of test compound which inhibits the growth of the test microorganism.
• a series of agar plates, each having the test compound incorporated at a specific concentration is inoculated with a fungal strain and each plate is then incubated for 48 h at 37 °C. The plates are examined for the presence or absence of fungal growth, and the relevant concentration is noted.
• Microorganisms which can be used in the test include Candida albicans,
• the in vivo evaluation of compounds of the present invention can be carried out at a series of dose levels by intraperitoneal or intravenous injection or by oral administration to mice which have been inoculated with a strain of fungus (e.g. Candida albicans). Activity is determined by comparing the survival of the treated group of mice at different dosage levels after the death of an untreated group of mice. The dose level at which the test compound provides 50% protection against the lethal effect of the infection is noted.
• a strain of fungus e.g. Candida albicans
• the compounds of the present invention substantially increase the solubility of the parent triazole antifungal compound and also release the bioactive parent compound (i.e. function as a prodrug) as demonstrated in human liver S9 experiments.
• Splitting patterns are designated as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad peak; dd, doublet of doublets; dt, doublet of triplets; and app d, apparent doublet, etc.
• Mass spectra were recorded on a Kratos MS-50 or a Finnegan 4500 instrument utilizing direct chemical ionization (DCI, isobutene), fast atom bombardment (FAB), or electron ion spray (ESI).
• DCI direct chemical ionization
• FAB fast atom bombardment
• ESI electron ion spray
• Analytical thin-layer chromatography was carried out on precoated silica gel plates (60F-254) and visualized using UV light, iodine vapors, and/or staining by heating with methanolic phosphomolybdic acid.
• Reverse phase chromatography was performed in a glass column using C18 silica gel (Waters Corporation Preparative C18 125 A) at pressures somewhat above atmospheric pressure.
• the pH of the aqueous layer was adjusted to 7.6 by addition of solid Na 2 CO 3 and then the organic and aqueous layers were separated.
• the aqueous layer was then subjected to reverse phase chromatography on 400 g of C-18 eluted with H 2 O to 5% CH 3 CN/ ⁇ 2 O.
• the product containing fractions were concentrated under reduced pressure, frozen and lyophilized to afford 1.5 g of the subtitled compound, I, as a white solid. (1.5 g, 12% over two steps).
• Di-tert-butyl chloromethyl phosphate, III may be made by any of the following methods.
• Silver di-t-butyl phosphate (6.34 g, 20 mmol), which was prepared by mixing di- t-butyl phosphate (obtained from di-t-butyl phosphite by the method of Zwierzak and Kluba, Tetrahedron, 1971 , 27, 3163) with one equivalent of silver carbonate in 50% aqueous acetonitrile and by lyophilizing to dryness, was placed together with chloroiodomethane (35 g, 200 mmol) in benzene and stirred at room temperature for 18 hrs. The reaction mixture was filtered and the filtrate concentrated under reduced pressure.
• Tetrabutylammonium di-t-butyl phosphate was prepared by dissolving di-t-butyl phosphate [ 20g, 94 mmol (obtained from di-t-butyl phosphite by the method of Zwierzak and Kluba, Tetrahedron, 1971, 27, 3163)] in methanolic tetrabutylammonium hydroxide (47 mL of 1M solution, 47 mmol). The reaction mixture had a temperature of 23 °C and pH of 4.33. The pH of the reaction mixture was adjusted to 6.5-7.0 by addition of methanolic tetrabutylammonium hydroxide (48 mL of 1M solution, 48 mmol) over 0.2 h.
• the reaction mixture was stirred for 0.5 h at approximately 26 °C and then was concentrated under reduced pressure at a bath temperature below 40 °C.
• the crude residue was azeotroped three times by adding toluene (3x100 mL) and then the mixture was concentrated under reduced pressure.
• the crude residue was then triturated in cold hexanes (0°C) for 1 h and then the solid was collected by filtration, washed with a minimum amount of cold hexanes and dried to give a first crop of tetrabutylammonium di-t-butyl phosphate as a white solid. (24. Og).
• the mother liquor was concentrated under reduced pressure and then triturated in cold hexanes (20 mL) for 1 h.
• Iodochloromethane (974 g, 402 mL, 5.53 mol) at 25°C was treated with tetrabutylammonium di-t-butylphosphate (250 g, 0.553 mol). The phosphate was added portion wise over 10 minutes. The heterogeneous mixture became a clear pink solution after approximately 15 minutes. The mixture was stirred for three hours, and the iodochloromethane was then removed by rotary evaporation with a bath temperature of ⁇ 30°C. The residue was taken up in 1 L t-butyl methyl ether and stirred for 15 minutes to precipitate tetrabutylammonium iodide by-product. Tetrabutylammonium iodide was removed by vacuum filtration through a sintered glass funnel. The filtrate was concentrated by rotary evaporation to an oil which contained a 5:1 mixture of III and undesired dimer impurity
• the mixture can be purified by a silica gel chromatography to obtain III as pure compound in ⁇ 60% yield as an oil.
• Step B To a round-bottom flask equipped with magnetic stirrer, cooling bath, pH probe and N 2 inlet-outlet was charged the product of Step A above (7.5 g) in CH 2 C1 2 (23 mL) and cooled to 0 °C. To this stirred solution, trifluoroacetic acid (8.8 mL) was added slowly and stirred for 3 h to complete the reaction. The completion of the reaction was judged by in-process HPLC. The reaction mixture was poured into a cold solution of 2N NaOH (64 mL). The reaction mixture was extracted with t-butyl acetate (2 x 65 mL) to remove all the organic impurities.
• the aqueous layer containing the title product as bis sodium salt was treated with activated charcoal (10 g) and filtered through a bed of Celite.
• the clear filtrate was acidified with IN HC1 to pH 2.5.
• the free acid, the title product was extracted into ethyl acetate (2 x 50 mL).
• the combined organic layer was washed with water, dried over MgSO 4) filtered, and the filtrate concentrated under reduced pressure to afford 3.39 g of crude title product.
• Example 2 A solution of title product of Example 2 was dissolved in 50 mL of ethyl acetate and to this was added t-butyl amine (5.3 mL) under nitrogen. The reaction mixture was stirred at 40 °C for about 1 hour to crystallize the product. The bis t- butyl amine salt was collected on a Buchner funnel and dried under vacuum to afford 2.21 g of the title compound as an off white crystalline solid.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• Oncology (AREA)
• General Chemical & Material Sciences (AREA)
• Communicable Diseases (AREA)
• Public Health (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Saccharide Compounds (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Plural Heterocyclic Compounds (AREA)
• Polymerization Catalysts (AREA)

Priority Applications (15)

Applications Claiming Priority (4)

Publications (1)

Family

ID=26873001

Family Applications (1)

Country Status (22)

Cited By (37)

Families Citing this family (12)

Citations (1)

Family Cites Families (16)

• 2001
  • 2001-01-10 US US09/757,438 patent/US6362172B2/en not_active Expired - Lifetime
  • 2001-01-16 PL PL356164A patent/PL206024B1/pl not_active IP Right Cessation
  • 2001-01-16 BR BR0107618-3A patent/BR0107618A/pt active Search and Examination
  • 2001-01-16 EP EP01942553A patent/EP1284737B1/en not_active Expired - Lifetime
  • 2001-01-16 KR KR1020027009320A patent/KR100748299B1/ko not_active Expired - Lifetime
  • 2001-01-16 IL IL15079801A patent/IL150798A0/xx active IP Right Grant
  • 2001-01-16 MX MXPA02007120A patent/MXPA02007120A/es active IP Right Grant
  • 2001-01-16 JP JP2001552899A patent/JP3766804B2/ja not_active Expired - Lifetime
  • 2001-01-16 NZ NZ519354A patent/NZ519354A/en not_active IP Right Cessation
  • 2001-01-16 AU AU29485/01A patent/AU782177C/en not_active Expired
  • 2001-01-16 CN CNB018038581A patent/CN1178665C/zh not_active Expired - Lifetime
  • 2001-01-16 WO PCT/US2001/001284 patent/WO2001052852A1/en not_active Ceased
  • 2001-01-16 CZ CZ20022822A patent/CZ20022822A3/cs unknown
  • 2001-01-16 HU HU0204405A patent/HU229226B1/hu not_active IP Right Cessation
  • 2001-01-16 AT AT01942553T patent/ATE300946T1/de active
  • 2001-01-16 DE DE60112433T patent/DE60112433T2/de not_active Expired - Lifetime
  • 2001-01-16 ES ES01942553T patent/ES2247131T3/es not_active Expired - Lifetime
  • 2001-01-16 RU RU2002118606/04A patent/RU2266909C2/ru active
  • 2001-01-16 DK DK01942553T patent/DK1284737T5/da active
  • 2001-01-16 CA CA2397734A patent/CA2397734C/en not_active Expired - Lifetime
  • 2001-01-16 PT PT01942553T patent/PT1284737E/pt unknown
• 2002
  • 2002-07-17 IL IL150798A patent/IL150798A/en unknown
  • 2002-07-19 NO NO20023468A patent/NO330352B1/no not_active IP Right Cessation

Patent Citations (1)

Also Published As

Similar Documents

Legal Events